Guest Editor Eun Ji Chung, Ph.D.
The articles in this special collection were prepared by undergraduate students majoring in biomedical engineering or chemical engineering who were enrolled in BME 459: Introduction to Nanomedicine and Drug Delivery at the Viterbi School of Engineering at the University of Southern California (USC) (Los Angeles, CA) in the spring of 2018. This upper-level course taught by Eun Ji Chung, Ph.D., covers topics in nanotechnology-based drug delivery systems, nano-based imaging and diagnostics, nanotechnology-based tissue engineering approaches, host response to nanomaterials, nanotoxicology and pharmacokinetics, in addition to aspects of regulatory affairs, teamwork and scientific and professional communication.
The special collection articles address topics relevant to nanoparticle targeting, drug delivery and diagnostics for cystic fibrosis (mucus-penetration, bacterial infections, gene therapy), ovarian cancer (siRNA therapy), pancreatic cancer (siRNA, microRNA, gene augmentation) and the use of hydrazones for controlled drug release (for cancer, inflammation, chelation, platelet aggregation).
The articles provide background on the different disease states, or in the case of hydrazones, the properties of the hydrazone bond; discuss current treatment options available in the clinic; and present nanoparticle-based approaches that can be applied to target specific diseases. Nanoparticles based on polymeric, metallic, lipids, proteins and carbohydrates are included and strategies that incorporate both passive targeting and active targeting with the use of ligands, such as peptides and antibodies, are shared.
This collection illustrates the growing use of nucleic acids for gene knockdown or augmentation. In addition, small interfering RNA (siRNA), microRNA (miR), short-hairpin RNA (shRNA) and plasmids combined with nanoparticles are highlighted along with explanations for how gene therapy in combination with drugs such as chemotherapy can be used as an effective strategy against cancer.
SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members. > READ MORE
April 8, 2019